Glucose homeostasis requires precise control of insulin secretion by pancreatic β-cells. This control is primarily ensured by glucose itself, but it also involves other nutrients and numerous neural and hormonal factors. Our understanding of stimulus secretion coupling in β-cells has considerably progressed through the use of in vitro models such as mouse or rat islets and cell lines. Recent work from various laboratories (rev. in 1) has led to the concept that nutrient-induced insulin secretion is controlled by a hierarchical interaction between two pathways that both depend on β-cell metabolism. The triggering, or ATP-sensitive K⁺ (K<sub>ATP</sub>) channel–dependent, pathway ultimately leads to a rise in the concentration of cytosolic Ca²⁺ that induces exocytosis of insulin granules. The amplifying, or K<sub>ATP</sub> channel–independent, pathway does not cause a further rise in cytosolic Ca²⁺ concentration but augments the secretory response to the triggering Ca²⁺ signal (1).

Studies of a biologically important phenomenon in experimental models have an obvious intrinsic scientific interest, but they are also expected to help elucidate the pathophysiology of human diseases, such as hyperinsulinemic hypoglycemia and diabetes. Therefore, in vitro studies with human islets are indispensable to assess whether the information collected with models is completely relevant and transposable to the human species.

Insulin secretion from isolated human islets was first measured 35 years ago (2). A number of studies have been published since, but, owing to the paucity of available material, they usually were very focused or fragmentary and based on a small number of islet preparations (3–12). More recently, technical progress in the procedures for isolation of human islets for transplantation have increased the possibilities of research with human β-cells. However, very often insulin secretion is only measured as a test of islet functionality, and the results typically show great variability and poorer responsiveness (small stimulation index) than in rodent islets. Other recent studies have used these islets to determine how human β-cells react and adapt to aggression by agents or conditions (β-cytotoxic drugs, cytokines, or high glucose or fatty acid concentrations) thought to be pathogenic in β-cell death or dysfunction occurring in type 1 or type 2 diabetes (13–22).

Despite the undisputable individual importance of all these contributions, the picture of nutrient control of insulin secretion in human islets is still built on data from heterogenous sources and remains incomplete. Such a basic reference is, however, necessary at a time when...
selective aspects of β-cell (dys)function in islets of type 2 diabetic patients start to be investigated (23–25). The aim of the current study was to define the major characteristics of insulin secretion induced by glucose and other nutrients in normal human islets studied in vitro in a dynamic system of perifusion.

**RESEARCH DESIGN AND METHODS**

The study was conducted within the framework of institutional programs of basic research and transplantation of human islets, which were approved by the local ethics committee (protocol UCL-HIA-001, authorization 2001/79) in accordance with the principles of the Declaration of Helsinki of 2000 and the guidelines defined by the Belgian authorities. Organ procurement and islet isolation. This study was performed with islets isolated from 16 human pancreas obtained (between April 2002 and May 2006) from multorgan donors through the Eurotransplant Network (Leiden, the Netherlands). Abdominal organs were perfused in situ with University of Wisconsin solution (4°C). The whole pancreas still attached to the duodenum was digested with Liberase HI in a polymethylpenten chamber, and the islets were purified on a discontinuous Ficoll-EuroCollins gradient. The whole procedure has been described in detail recently (26). The final purity (assessed by dithizone staining) and viability (assessed by trypan blue exclusion) of the islets (26) averaged 68% (range 16–60), mean BMI 24.4 kg/m² (18.0–29.4). On arrival, the pancreas was digested with Liberase HI in a polymethylpenten chamber, and the islets were purified on a discontinuous Ficoll-EuroCollins gradient. The whole procedure has been described in detail recently (26). The final purity (assessed by dithizone staining) and viability (assessed by trypan blue exclusion) of the islets (26) averaged 68% (range 30–95) and 87% (70–95), respectively. The fraction of islets dedicated to studies of insulin secretion was cultured at 37°C in RPMI medium containing 10% heat-inactivated FCS, 100 μg/ml penicillin, 100 IU/ml streptomycin, and 5 mmol/l glucose, in an atmosphere of 95% air/5% CO₂.

**Measurements of insulin secretion.** Depending on the amount of islets made available to in vitro studies, the experiments could be performed during 1 day, 2 days (6 of 16), or 3 consecutive days (4 of 16). The mean time elapsed between the start of islet culture and the start of the experiments was 46 h (range 28–88).

The medium used for measurement of insulin secretion contained in mmol/l: 120 NaCl, 4.8 KCl, 2.5 CaCl₂, 1.2 MgCl₂, and 24 NaHCO₃. It was continuously gassed with a mixture of O₂/CO₂ (94:6% ratio) and was supplemented with 1 mg/ml BSA (fraction V; Roche, Basel, Switzerland) and appropriate concentrations of glucose and test substances. When the concentration of KCl was increased to 30 mmol/l, that of NaCl was decreased accordingly. Ca²⁺-free solutions were prepared by substitution of CaCl₂ with MgCl₂ and the addition of 100 μmol/l EGTA. Palmitate (100 μmol/l in 0.1 mol/l NaOH) was added at different concentrations to a medium containing different concentrations of fatty acid-free BSA (Roche), as previously reported in detail (27).

At the end of the culture period, the islets were placed in the chambers of the same perfusion system as that used for studying insulin secretion in mouse islets (28). All experiments began with a 60-min equilibration period, usually followed by a 120-min period of stimulation with various test agents (small variations are indicated in the figure legends). Changes in the medium composition are shown at the top of each figure.

The islets used in each experiment were not counted but, at the end, were recovered from the chambers and transferred into acid-ethanol for insulin extraction. Insulin, in the effluent fractions (collected at 2-min intervals) and the diluted extracts, was measured by double-antibody radioimmunoassay using human insulin as a standard. The fractional insulin secretion rate was calculated as the percent of islet insulin content that was secreted per minute. Results are thus presented as the fractional insulin secretion rates (means ± SE) for perifusions performed with the indicated number of different islet preparations. Owing to the limited number of chambers and amount of tissue, it was not always possible to compare the effects of test agents at different glucose concentrations with islets from the same preparations. The number of paired experiments is given in the figure legends.

When not indicated otherwise, reagents were from Sigma (St. Louis, MO) or Merck (Darmstadt, Germany). Diazoxide (a gift from Schering-Plough, Brussels, Belgium) and tolbutamide were added from freshly prepared stock solutions in 0.1 mol/l NaOH. Forskolin (Calbiochem-Behring, San Diego, CA) was added from a 1 mmol/l stock solution in DMSO.

**RESULTS**

**Stimulation of insulin secretion by glucose.** After 60 min of perifusion in the absence of glucose, human islets were stimulated by stepwise increases in the glucose concentration (Fig. 1). This resulted in a concentration-dependent increase in insulin secretion between 3 and 15 mmol/l glucose, with no consistent further stimulation at higher glucose levels. Supplementation of the medium with 1 μmol/l forskolin, to increase cAMP levels, did not alter the glucose dependency but approximately doubled the secretory response at each glucose concentration above 1 mmol/l (Fig. 1A). The secretory rate kept increasing slightly above 15 mmol/l glucose in a few preparations. Without and with forskolin, one islet preparation showed a small, transient response to 1 mmol/l glucose, and four to
five of the eight preparations were stimulated by 3 mmol/l glucose. Glucose-induced insulin secretion was readily reversible when the glucose concentration was lowered from 10 to 1 mmol/l, but sometimes it exhibited a transient further increase when glucose was decreased from 30 to 7 mmol/l (Fig. 1). These experiments thus show that the glucose-dependency curve of insulin secretion by human islets in vitro is sigmoidal but shifted to the left compared with rodent islets, with a threshold at \( \frac{1}{11} \) mmol/l, half-maximum stimulation at \( \frac{1}{6.5} \) mmol/l, and maximum stimulation at \( \frac{1}{15} \) mmol/l (Fig. 1B). Basal (no glucose) and maximal (30 mmol/l glucose) rates of insulin secretion averaged 0.005 \pm 0.001 and 0.074 \pm 0.008\% per min (\( \approx 15\)-fold increase) in the absence of forskolin and 0.003 \pm 0.001 and 0.161 \pm 0.019\% per min (\( \approx 27\)-fold increase) in the presence of forskolin.

Stimulation of human islets by a rapid increase in the glucose concentration from 1 to 15 mmol/l induced biphasic insulin secretion characterized by a sharp and marked first phase and a lower but sustained second phase (Fig. 2A). Basal, peak first-phase (5–8 min), and second-phase (21–30 min) insulin secretion averaged 0.008 \pm 0.001, 0.147 \pm 0.020 (\( \approx 18\)-fold increase), and 0.078 \pm 0.013\% per min (\( \approx 10\)-fold increase). The addition of diazoxide, an effective opener of \( K_{ATP} \) channels in human \( \beta \)-cells (29), suppressed glucose-induced insulin secretion, whereas subsequent closure of the channels by tolbutamide (29,30) completely reversed the inhibition. The addition of forskolin augmented the secretory rate within 5 min. Finally, withdrawal of all drugs and return to a nonstimulatory medium lowered the insulin secretion rate without delay (Fig. 2B). The presence of forskolin during the whole experiment augmented the amplitude of first-phase (\( \approx 50\%) \) and second-phase (\( \approx 70\%) \) glucose-induced insulin secretion, but it did not alter the kinetics nor affect the inhibitory and stimulatory effects of diazoxide and tolbutamide (Fig. 2B). No significant alteration of glucose-induced insulin secretion was observed over the short (2–3 days) period of islet culture.

We next tested whether glucose can increase insulin secretion via a \( K_{ATP} \) channel–independent or amplifying pathway. Figure 3 shows that tolbutamide, purportedly used at the high concentration of 500 \( \mu \)mol/l to block all \( K_{ATP} \) channels (29,30), and 30 mmol/l KCl, used to depolarize islets...
larize β-cells despite opening of K<sub>ATP</sub> channels by diazoxide (31), rapidly increased insulin secretion in 1 mmol/l glucose. Subsequent stimulation with 15 mmol/l glucose further increased the secretory rate. This effect was faster and more completely reversible in the presence of tolbutamide (Fig. 3A) compared with KCl plus diazoxide (Fig. 3B). In both cases, inhibition of ATP production by azide markedly inhibited insulin secretion.

Stimulation of insulin secretion by amino acids. Arginine (10 mmol/l) induced a small monophasic secretion of insulin in human islets perfused with a medium containing 3 mmol/l glucose (Fig. 4A). The response to arginine was larger in the presence of 25 μmol/l tolbutamide, which itself caused a sustained increase in secretion, and even more so in the presence of 15 mmol/l glucose (Fig. 4A). The secretory responses to arginine (areas above pre-stimulatory values) averaged (% of content in 10 min): 0.11 ± 0.01 in 3 mmol/l glucose, 0.23 ± 0.02 in 3 mmol/l glucose plus tolbutamide, and 0.61 ± 0.08 in 15 mmol/l glucose plus tolbutamide.

We then studied the effects of a mixture of four amino acids (1 mmol/l alanine, 1 mmol/l leucine, 1.5 mmol/l lysine, and 1.5 mmol/l glutamine) chosen as representative of the major classes of amino acids and used at a total concentration of 5 mmol/l (approximately twofold higher than the total concentration of amino acids in human plasma) (32). As shown in Fig. 4B, the amino acid mixture was very efficient in inducing insulin secretion, and its effect increased with the concentration of glucose, at least up to 10 mmol/l. Alanine alone (10 mmol/l) rapidly and reversibly increased insulin secretion by human islets, and its effect was larger in 7 than 3 mmol/l glucose: 0.54 ± 0.10 vs. 0.16 ± 0.04% of content in 20 min (data not shown).

In rodent islets, the combination of leucine and glutamine potently increases insulin secretion through allosteric stimulation of glutamate dehydrogenase (by leucine) and provision of carbons to the Krebs cycle (by...
both leucine and glutamine) (33,34). As shown in Fig. 5A, the two amino acids (5 mM each) induced biphasic insulin secretion from human islets in the presence of 3 mM glucose. Their effect was markedly potentiated by forskolin and abolished by omission of extracellular Ca²⁺.

The nonmetabolized leucine analog 2-amino-bicyclo[2,2,1]-heptane-2-carboxylic acid (BCH), which also activates glutamate dehydrogenase (34), was very efficient alone (at 10 mM), but its effect was smaller in 7 than 3 mM glucose (Fig. 5B), possibly because glutamate dehydrogenase activity decreases at higher glucose levels (33).

Alone, glutamine does not increase insulin secretion in rodent islets (33,35). As shown in Fig. 5C, supplementation of a glucose-free medium with 2 mM glutamine did not influence basal insulin secretion in human islets or obviously alter their response to increasing glucose concentrations. Only one of six islet preparations was stimulated by 1 mM glucose, and four of six responded to 3 mM glucose. Subsequent addition of 5 mM BCH rapidly evoked insulin secretion, which immediately decreased on removal of glucose (Fig. 5C).

**Stimulation of insulin secretion by fatty acids.** The acute effects of fatty acids on insulin secretion from rodent islets depend on the concentration of their unbound fraction rather than on their total concentration (27,36). We therefore tested two concentrations of palmitate in the presence of two concentrations of BSA. As shown in Fig. 6, in the presence of 65 μM BSA (4.4 mg/ml), palmitate was ineffective at 130 μM and caused a 35–50% increase in insulin secretion at 325 μM. This stimulation was rapidly abolished by increasing the albumin concentration 2.5-fold, while keeping constant the concentration of palmitate; thus, the ratio of palmitate to BSA was lowered from 5 to 2. The effects were similar in 3 and 7 mM glucose. The insulin-secreting action of palmitate was thus clearly dependent on its unbound fraction.

**Stimulation of insulin secretion by various metabolites.** Unlike rat islets, mouse islets do not secrete insulin when stimulated by membrane-permeant dimethylsuccinate. This species difference has been attributed to the lack of malic enzyme in mouse β-cells (37). As shown in Fig. 7A, 5 mM dimethylsuccinate reversibly increased insulin secretion in human islets at 3 and 10 mM glucose. This effect is in agreement with the presence of malic enzyme in human islets (37). As in both mouse and rat islets, dimethylglutamate and methylpyruvate (5 mM) were effective insulin secretagogues in human islets (Fig. 7A). Whereas the effect of dimethylglutamate is probably entirely attributable to changes in β-cell metabolism (34), that of methylpyruvate may include both changes in metabolism (38) and a direct inhibitory action on Kᵦᵦᵦ channels (39).

In mouse islets, the purine ribonucleoside inosine is split to hypoxanthine and ribose-1-phosphate, which is then metabolized (40), leading to insulin secretion by mechanisms largely resembling those of glucose-induced secretion (41). As shown in Fig. 7B, 5 mM inosine potently and reversibly increased insulin secretion in human islets at both 3 and 10 mM glucose. The effect of inosine was not smaller than that of an equivalent glucose concentration. Pyruvate, lactate, and fructose (10 mM)
did not increase insulin secretion in two islet preparations perfused at 3 and 10 mmol/l glucose (data not shown).

DISCUSSION
In this study, we show that glucose-stimulated insulin secretion in isolated human islets is characterized by a sigmoidal concentration-dependency curve that is shifted to the left compared with mouse or rat islets. This shift is entirely compatible with the lower plasma glucose levels in humans versus rodents. Only one similar, complete concentration-dependency curve has previously been published. It was based on incubation of islets from three subjects and had a small stimulation index (fourfold), but it was also shifted to the left compared with rodent islets (5). Comparing the glucose dependency of insulin secretion in vitro and in vivo is problematic for several reasons, including the confounding influence of various factors on β-cells in situ, the necessity of using deconvolution techniques to estimate secretion rates from changes in plasma insulin or C-peptide concentrations, and the difficulty (impossibility) of imposing a wide range of blood glucose concentrations permitting definition of threshold, \( K_m \) and \( V_{max} \). Nevertheless, there is agreement that the major changes in plasma insulin levels (42,43) or insulin secretion rates (44) occur between 5 and 10 mmol/l glucose, which is in keeping with a \( K_m \) at 6.5 mmol/l in vitro. The amplitude of the changes in the insulin secretion rate that we measured in vitro is also commensurate with that of changes observed in vivo (44).

The maximally effective concentration of glucose in vivo is not precisely known because blood glucose levels are only exceptionally raised higher than 15 mmol/l. When this occurred, no saturation of plasma insulin levels was observed (42), or a half-maximum elevation of C-peptide levels was calculated at 14 mmol/l glucose (45). Our observation that insulin secretion by human islets plateaued at ~15 mmol/l glucose in vitro, when the glucose was tested alone, cannot be explained by exhaustion because forskolin doubled the insulin secretory rate to a value corresponding to ~10% of the islet insulin content per hour. Moreover, an amino acid mixture caused a further increase in insulin secretion in 20 mmol/l glucose. The influence of nonglucose stimuli (nutrient and others) could thus explain the difference between in vitro and in vivo observations, if the latter prove to adequately reflect insulin secretion rates.

A threshold glucose concentration at 3–4 mmol/l in isolated human islets is clearly lower than in rodent islets. This observation may explain why in this and other studies, several agents, like arginine (25,46), alanine, an amino acid mixture, and palmitate (12), were effective at this low glucose concentration, whereas they are not effective in rodent islets. It also helps our understanding of how insulin secretion can be controlled in vivo at low physiological blood glucose levels. The threshold has not been defined in vivo, but the insulin secretion rate increases between 3 and 5 mmol/l glucose in fasted subjects (47). Finally, our findings have practical implications for the evaluation of the functionality of human islets. Traditional measurements of insulin secretion at 3 mmol/l glucose do not always identify the basal secretory rate, which contributes to the low stimulation index reported in many studies.

Glucose-induced insulin secretion in rodent islets depends on the metabolism of the glucose, which is largely controlled by the high-\( K_m \) glucokinase (48). Human β-cells also contain glucokinase (49,50) and metabolize glucose in a concentration-dependent manner between 1 and 15 mmol/l glucose (5,50) to produce an increase in the ATP-to-ADP ratio between 1 and 10 mmol/l glucose (51). The occurrence of insulin secretion at lower glucose concentrations in human β-cells compared with rodent β-cells does not imply the participation of another phosphorylating enzyme. The properties of glucokinase permit control of phosphorylation between 1 and 3 mmol/l glucose (48). It is also important to bear in mind that the threshold of glucose-stimulated insulin secretion is reached at the glucose concentration where the rate of metabolism closes enough K\(_{\text{ATP}}\) channels to depolarize the membrane up to the threshold potential for activation of voltage-dependent Ca\(^{2+}\) channels. Subtle differences in the number or properties of ionic channels might explain the shift between human and rodent β-cells.

Stimulation of human islets by an abrupt increase in the glucose concentration induced biphasic insulin secretion with a prominent first phase followed by a sustained, flat second phase. This time course, also observed in other studies (7,13,21,52), is similar to that of insulin secretion in the perfused mouse pancreas (53,54) or perfused mouse islets (28,55) and contrasts with the ascending second phase seen in rat preparations (53,55,56). It has recently been reported that in mice, as in humans, plasma insulin levels increase with a biphasic time course and an increasing second phase during hyperglycemic clamps (28,57). The pattern of the in vitro and in vivo insulin responses is thus apparently discrepant in both species.

Not only are the kinetics of glucose-stimulated insulin secretion similar in perfused human and mouse islets, but the fractional rates of secretion are also comparable during both the first and second phases (28). The variability of the responses of human islets is often emphasized. In the 14 perfusions studying insulin secretion in response to 15 mmol/l glucose alone (Fig. 2A), the second phase was characterized by a coefficient of variation (CV) of 67%, compared with a CV of 46% in 20 similar perfusions with mouse islets (28). Based on these large numbers of experiments, the difference is not a major one, perhaps because insulin secretion is normalized to the islet insulin content.

Three major features of the glucose control of insulin secretion in rodent islets also characterize human islets. First, the critical role of K\(_{\text{ATP}}\) channels is convincingly demonstrated by the abrogation of insulin secretion with diazoxide and its reversible restoration with tolbutamide. Patch-clamp studies have shown that K\(_{\text{ATP}}\) channels in human β-cells are similar to those in rodent β-cells (29,30). Second, the K\(_{\text{ATP}}\) channel-independent amplifying pathway is also functional. Thus, in agreement with a study using incubated human islets (10), glucose increased insulin secretion when β-cell K\(_{\text{ATP}}\) channels were completely closed with a sulfonylurea or held open with diazoxide in the presence of depolarizing KCl. Measurements of β-cell cytosolic Ca\(^{2+}\) will be necessary to establish whether this amplification reflects an augmentation of secretion without a further rise in the triggering Ca\(^{2+}\) signal, as in rodent islets (31). Third, glucose potentiates insulin secretion induced by arginine or a mixture of amino acids. Glucose potentiates of insulin secretion induced by nonmetabolized nutrients, such as arginine, has attracted much attention because the process is impaired in type 2 diabetic patients (58,59). Using mouse islets, we have recently explained the phenomenon by both an augmen-
tion of cytosolic Ca$^{2+}$ and an amplification of the response to Ca$^{2+}$ (60). Our results showing that arginine-induced insulin secretion is also potentiated by tolbutamide, albeit to a lesser extent than by glucose, are in keeping with in vivo studies in humans (61) and in vitro studies with rodent models (details and mechanisms in 60).

Amino acids participate in physiological control of insulin secretion. Regulation of β-cell glutaminolysis at the level of glutamate dehydrogenase is important for that process. Glutamate dehydrogenase can be activated by leucine or its nonmetabolized analog BCH, and it can be inhibited by glucose via the increase in ATP and GTP (33). The combination of leucine and glutamine doubled insulin secretion in 3 mmol/l glucose, but BCH alone was at least as effective, suggesting that the intracellular pool of glutamine is sufficient after islet culture, a conclusion also supported by the lack of effect of 2 mmol/l glutamine on insulin secretion induced by threshold glucose concentrations. One observation points to the preeminence of glucose over glutamine metabolism for insulin secretion. Removal of glucose from a medium containing both BCH and glutamine immediately and markedly decreased insulin secretion, indicating that the positive effect of 5 mmol/l glucose predominates over the inhibitory action that it might exert on glutamate dehydrogenase. However, this observation does not detract from the relevance of amino acids for the control of insulin secretion in vivo. Thus, at the slightly supraphysiological concentration of 5 mmol/l, a mixture of four amino acids was very potent in increasing insulin secretion from a threshold to a maximally effective concentration of glucose (3–20 mmol/l).

The role of fatty acids for the acute regulation of insulin secretion in vivo is controversial, but it is generally considered to be less than that of amino acids. Our in vitro data directly support this view because effects of palmitate on insulin secretion by perfused human islets were only seen at the nonphysiological high palmitate-to-BSA ratio of 5. Palmitate and other fatty acids, used at a fatty acid-to-BSA ratio of 3.4, have been found to increase insulin secretion by human islets incubated in 3.3–16.7 mmol/l glucose (12). In this respect, human islets thus behave like mouse and rat islets (27,36). We acknowledge, however, that some in vivo studies reported an increase in the insulin secretion rate at a stable 5 mmol/l glucose when an infusion of fatty acids plus heparin acutely raised the fatty acid–to-albumin ratio to ~2.0 (62). This ratio, however, rarely exceeds 1 under physiological conditions.

In conclusion, nutrient-induced insulin secretion in normal human islets is larger than often reported. Its characteristics globally resemble those observed in rodent islets, with both triggering and amplifying pathways. The pattern of the biphasic response to glucose is superimposable on that in mouse islets, but the concentration-response curve is shifted to the left, and various nutrients, in particular amino acids, influence insulin secretion at physiological glucose concentrations. Overall, this study provides a reference for the characterization of the secretory defects in islets from type 2 diabetic patients.

ACKNOWLEDGMENTS

This work was supported by the Fondation Louvain of the Catholic University of Louvain; the National Fund for Scientific Research, Brussels (3.4552.04); and by the Direc- torate for Scientific Research of the French Community of Belgium (ARC 05/10-328).

We are grateful to R.M. Goebbles and F. Knockaert for their expert technical assistance and V. Lebec for editorial help.

REFERENCES

1. Henquin JC, Ravier MA, Nenquin M, Jonas JC, Gilon P: Hierarchy of the β-cell signals controlling insulin secretion. Eur J Clin Invest 33:742–750, 2003
2. Ashcroft SJH, Bassett JM, Randle PJ: Isolation of human pancreatic islets capable of releasing insulin and metabolising glucose in vitro. Lancet 297:888–890, 1971
3. Andersson A, Berg H, Groth CG, Gunnarsson R, Hellerström C, Lundgren G, Westman J, Ostman J: Survival of isolated human islets of Langerhans maintained in tissue culture. J Clin Invest 57:1295–1301, 1976
4. Grant AM, Christie MR, Ashcroft SJH: Insulin release from human pancreatic islets in vitro. Diabetologia 19:114–117, 1980
5. Harrison DE, Christie MR, Gray DWR: Properties of isolated human islets of Langerhans: insulin secretion, glucose oxidation and protein phosphorylation. Diabetologia 28:99–103, 1985
6. Rhodes CJ, Campbell IL, Szopa TM, Biden TJ, Reynolds PD, Fernando ON, Taylor KW: Effects of glucose and α-β-hydroxybutyrate on human pancreatic islet cell function. Clin Sci 85:567–572, 1985
7. Misler S, Barnett DW, Gillis KD, Pressel DM: Electrophysiology of stimulus-secretion coupling in human β-cells (Review). Diabetes 41:1221–1228, 1992
8. Kindmark H, Köhler M, Arkhammar P, Efendic S, Larsson O, Linden S, Nilsson T, Berggren FO: Oscillations in cytoplasmic free calcium concentration in human pancreatic islets from subjects with normal and impaired glucose tolerance. Diabetologia 37:1121–1131, 1994
9. Marchetti P, Scharp DW, Mclear M, Gingerich R, Finke E, Olack B, Swanson C, Giannarelli R, Navales R, Lacy PE: Pulsatile insulin secretion from isolated human pancreatic islets. Diabetes 43:827–830, 1994
10. Straub SG, James RF, Dunne MJ, Sharp GW: Glucose activates both KATP channel-dependent and KATP channel-independent signaling pathways in human islets. Diabetes 47:735–743, 1998
11. Squires PE, Harris TE, Persaud SJ, Curtis SB, Buchanan AM, Jones PM: The extracellular calcium-sensing receptor on human β-cells negatively modulates insulin secretion. Diabetes 49:409–417, 2000
12. Gravena C, Mathias PC, Ashcroft SJH: Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J Endocrinol 173:73–80, 2002
13. Davalli AM, Ricordi C, Socci G, Braghi S, Bertuzzi F, Fattor B, Di Carlo V, Pontiroli AE, Pozza G: Abnormal sensitivity to glucose of human insulin cells in a high glucose medium: partial reversibility after an additional culture in a normal glucose medium. J Clin Endocrinol Metab 72:202–208, 1991
14. Rizik DL, Peipeleers DG, Ling Z, Welsh N, Hellerström C, Andersson A: Major species differences between humans and rodents in the susceptibility to pancreatic β-cell injury. Proc Natl Acad Sci U S A 91:9254–9256, 1994
15. Ling Z, Peipeleers DG: Prolonged exposure of human β-cells to elevated glucose levels results in sustained cellular activation leading to a loss of glucose regulation. J Clin Invest 98:2805–2812, 1996
16. Corbett JA, Kwon G, Marino MH, Rodi CP, Sullivan PM, Turk J, McDaniel ML: Tyrosine kinase inhibitors prevent cytokine-induced expression of iNOS and COX-2 by human islets. Am J Physiol 270:C1581–C1587, 1996
17. Marshak S, Leibowitz G, Bertuzzi F, Socci C, Kaiser N, Gross DJ, Cerasi E, Melloul D: Impaired β-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 48:1230–1236, 1999
18. Bjorklund A, Lanzner A, Grill VE: Glucose-induced [Ca$^{2+}$]), abnormalities in human pancreatic islets: important role of overstimulation. Diabetes 48:1540–1548, 2000
19. Giannoukakis N, Rudert WA, Trucco M, Robbins PD: Protection of human islets from the effects of interleukin-1β by adenosinergic gene transfer of an I$_β$B repressor. J Biol Chem 275:36509–36513, 2000
20. Maeder K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka H, Spinas GA, Kaiser N, Halban PA, Donath MI: Glucose-induced β-cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851–860, 2002
21. Song SH, Rhodes CJ, Veldhuis JD, Butler PC: Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. Endocrinology 144:3399–3405, 2003
22. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti
P. Del Prato S. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ, in the modulation of insulin secretion. *Am J Physiol 280:E560–E567, 2004*

23. Fernandez-Alvarez J, Conger I, Rasschaert J, Sener A, Gomis R, Malaisse WJ. Enzymatic, metabolic and secretory patterns in human islets of type 2 (non-insulin-dependent) diabetic patients. *Diabetologia 37:177–181, 1994*

24. Deng S, Vatamanuik M, Huang X, Doliba N, Lian MM, Frank A, Velidedeoglu E, Desal MI, Koeberlein B, Wolf B, Barker CF, Naji A, Matschinsky FM, Markmann JF. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. *Diabetes 53:624–632, 2004*

25. Anello M, Lapi R, Spampinato D, Piro S, Masini M, Boggi U, Del Prato S, Rabbuazo AM, Purrello F, Marchetti P. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. *Diabetologia 48:282–288, 2005*

26. Dufrane D, Goebelbs RM, Guiot Y, Sfiffiet JP, Henquin JC, Gianello P. A simple method using a polyethylene plastic chamber for isolation of human pancreatic islets. *Pancres 30:e51–e60, 2005*

27. Warnotte C, Nenquin M, Henquin JC: Unbound rather than total concentration and saturation rather than unsaturation determine the potency of fatty acids on insulin secretion. *Mol Cell Endocrinol 153:147–153, 1999*

28. Henquin JC, Nenquin M, Stieret P, Ahren B. In vivo and in vitro glucose-induced biphasic insulin secretion in the mouse: pattern and role of cytoplasmic Ca2+ and amplification signals in β-cells. *Diabetes 55:441–451, 2006*

29. Misler S, Gee WM, Gillis KD, Scharp DW, Falke LC. Metabolite-regulated ATP-sensitive K+ channel in human pancreatic islet cells. *Diabetes 38:422–427, 1989*

30. Ashcroft FM, Nenquin M, Henquin JC. ATP- and tolbutamide-sensitivity of the ATP-sensitive K-channel from human pancreatic β-cells. *Diabetologia 32:591–598, 1989*

31. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. *Diabetes 49:1751–1790, 2000*

32. Van Loo LC, Saris WHM, Verhagen H, Wagenmakers AJM. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *Am J Clin Nutr 72:96–105, 2000*

33. MacDonald MJ, Fahien LA, Gray DW, Sutton R. A: ATP and tolbutamide-sensitivity of the ATP-sensitive K-channel from human pancreatic β-cells. *Diabetes 92:96–105, 2000*

34. MacDonald MJ, Fahien LA, Gray DW, Sutton R. The ATP- and tolbutamide-sensitivity of the ATP-sensitive K-channel from human pancreatic β-cells. *Diabetologia 32:591–598, 1989*

35. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. *Diabetes 49:1751–1790, 2000*

36. Parker SM, Moore PC, Johnson LM, Poitout V. Palmitate potentiation of glucose-stimulated insulin secretion in health and in diabetes: some re-evaluations and proposals. *Diabetologia 11:1–13, 1975*

37. Davalli AM, Pontiroli AE, Soci C, Bertuzzi F, Fattor B, Braghi S, Di Carlo V, Pozza G: Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli given acutely: evidence supporting specific desensitization rather than β-cell exhaustion. *J Clin Endocrinol Metab 74:790–794, 1992*

38. Byrne MM, Sturis J, Polonsky KS. Inulin secretion and clearance during low-dose graded glucose infusion. *Am J Physiol 268:E21–E27, 1995*

39. Ashcroft FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, Taub R, Grimsby J. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. *Diabetes 55:1–12, 2006*

40. Bedoya FJ, Wilson JM, Ghosh AK, Finegold D, Matschinsky FM. The glucokinase glucose sensor in human pancreatic islet tissue. *Diabetes 35:61–67, 1986*

41. De Vos A, Heimberg H, Quartier E, Huyppens P, Bouwens L, Pipeleers D, Schuit F. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. *J Clin Invest 96:2489–2495, 1995*

42. Cerasi E. Mechanisms of glucose stimulated insulin secretion in health and in diabetes: some re-evaluations and proposals. *Diabetologia 11:1–13, 1975*

43. Rudsenski AS, Hosker JP, Burnett MA, Matthews DR, Turner RC. The beta cell glucose stimulus-response curve in normal humans assessed by insulin and C-peptide secretion rates. *Metabolism 37:526–534, 1988*

44. Polonsky KS. Lilly Lecture 1994: The β-cell in diabetes: from molecular genetics to clinical research. *Diabetes 44:705–717, 1995*

45. Van Haften TW, Boonstra E, Veneman TF, Gerich JE, van der Veen EA. Dose-response characteristics for glucose-stimulated insulin release in man and assessment of influence of glucose on arginine-stimulated insulin release. *Metabolism 39:1292–1299, 1990*

46. Davalli AM, Pontiroli AE, Soci C, Bertuzzi F, Fattor B, Braghi S, Di Carlo V, Pozza G: Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli given acutely: evidence supporting specific desensitization rather than β-cell exhaustion. *J Clin Endocrinol Metab 74:790–794, 1992*

47. Byrnes MM, Sturis J, Polonsky KS. Inulin secretion and clearance during low-dose graded glucose infusion. *Am J Physiol 268:E21–E27, 1995*

48. Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, Taub R, Grimsby J. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. *Diabetes 55:1–12, 2006*

49. Bedoya FJ, Wilson JM, Ghosh AK, Finegold D, Matschinsky FM. The glucokinase glucose sensor in human pancreatic islet tissue. *Diabetes 35:61–67, 1986*

50. De Vos A, Heimberg H, Quartier E, Huyppens P, Bouwens L, Pipeleers D, Schuit F. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. *J Clin Invest 96:2489–2495, 1995*

51. Detimary P, Dejonghe S, Linz Z, Pipeleers D, Schuit F, Henquin JC. The changes in adenine nucleotides measured in glucose-stimulated rodent islets occur in β-cells but not in α-cells and are also observed in human islets. *J Biol Chem 273:33995–33998, 1998*

52. Ricordi C, Lacy PE, Finke EH, Ollak BJ, Scharp DW. Automated method for isolation of human pancreatic islets. *Diabetes 37:413–420, 1988*

53. Lenzen S. Insulin secretion by isolated perfused rat and mouse pancreas. *Am J Physiol 236:E391–E400, 1979*

54. Berglund O. Different dynamics of insulin secretion in the perfused pancreas of mouse and rat. *Acta Endocrinol 93:54–60, 1980*

55. Zawalich WS, Bonnet-Eymard M, Zawalich KC. Insulin secretion, inositol phosphate levels, and phospholipase C isozymes in rodent pancreatic islets. *Metabolism 49:1156–1163, 2000*

56. Curry DL, Bennett LL, Godsky GM. Dynamics of insulin secretion by the perfused rat pancreas. *Endocrinology 93:572–584, 1978*

57. Nunemaker CS, Waterman DH, McGuiness OP, Sweet IR, Teague JC, Satin LS. Insulin secretion in the conscious mouse is biphasic and pulsatile. *Am J Physiol 260:E523–E529, 2000*

58. Efendic S, Cerasi E, Luft R. Quantitative study on the potentiating effect of arginine on glucose-induced insulin secretion in healthy, prediabetic, and diabetic subjects. *Diabetes 23:161–171, 1974*

59. Ward WK, Boligano DC, McKnight B, Halter JB, Porte D Jr. Diminished B-cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. *J Clin Invest 74:1318–1328, 1984*

60. Ishiyama N, Ravier MA, Henquin JC. Dual mechanism of the potentiation by glucose of insulin secretion induced by arginine and tolbutamide in mouse islets. *Am J Physiol 290:E543–E549, 2006*

61. Pfeifer MA, Halter JB, Graf F, Porte Jr: Potentiation of insulin secretion to nonglucotic stimuli in normal man by tolbutamide. *Diabetes 29:335–340, 1980*

62. Boden G, Chen X. Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. *Diabetes 48:577–583, 1999*